recombinant thyroid-stimulating hormone

Phase 3Biologic

recombinant thyroid-stimulating hormone is one of 58 biologic programs targeting Chronic Lung Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lung DiseaseActive, not recruiting

Thyroid CancerActive, not recruiting

Chronic Lung DiseasePhase 1

Active, not recruiting

Thyroid CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Depakote

AbbVie

Phase 2

2 5

Iclusig

Takeda

Phase 2

2 6

17-AAG

Bristol-Myers Squibb

Phase 2

1 7

Lithobid

SSolvay Pharmaceuticals

Phase 2

2 8

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Phase 2

1 9

Camptosar

EEastern Cooperative Oncology Group

Phase 2

1 10

Ofev

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer

Unknown status·UUniversity College, London·Phase 3·NCT00415233·438 enrolled

Chronic Lung Disease1 trial

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease

Active, not recruiting·UUniversity College, London·Phase 1·NCT05898633·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for recombinant thyroid-stimulating hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant thyroid-stimulating hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant thyroid-stimulating hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity College, London

recombinant thyroid-stimulating hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Cancer1 trial

Chronic Lung Disease1 trial

References

Drug Info

Quick Facts

Related News